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In this study, we examined the effects of cholecalciferol,
a primary keratinocyte metabolite and precursor of the
hydroxylated form of vitamin D3, 1a,25-dihydroxyvita-
min D3 [1a,25(OH)2D3], on prostaglandin E2 (PGE2)
production in human keratinocytes by examining its
respective effects on cyclooxygenase-1 (COX-1), cyclo-
oxygenase-2 (COX-2), and cytosolic phospholipase A2
(cPLA2) expression, the rate-limiting enzymes regulating
PGE2 biosynthesis and differentiation of keratinocytes.
Cholecalciferol induced PGE2 production, whereas
1a,25(OH)2D3 had no effect on PGE2 production both
in normal human epidermal keratinocytes and in the
immortalized human keratinocyte cell line, HaCaT. In
HaCaT cells, neither COX-1 mRNA nor protein was
detectable without stimulation and COX-1 expression
did not increase in response to cholecalciferol treatment.
Although cPLA2 mRNA and protein were constitutively
expressed in untreated HaCaT cells, expression levels did
Prostaglandin (PG) biosynthesis is a two-step process that isdependent upon the release of arachidonic acid (AA) frommembrane phospholipids by phospholipase A2 (PLA2) andthe subsequent conversion of AA to PG by cyclooxygenase(COX); PG play important roles in a variety of patho-
physiologic processes (DeWitt, 1991; Kujubu et al, 1991; O’Banion
et al, 1991; Kudo et al, 1993; Serhan et al, 1996). The AA signal
transduction cascade is most often associated with intracellular pathways
that modulate cellular proliferation and differentiation (Ruzicka, 1990;
Pentland and Needleman, 1986). Endogenous prostaglandin E2 (PGE2)
has been shown to modulate the differentiation of keratinocytes (Evans
et al, 1993), which continuously undergo this process to renew the
epidermis, a tissue that is a significant producer of PG itself (Jonsson
et al, 1972). Vitamin D3 is also a well-known inducer of keratinocyte
differentiation (Hosomi et al, 1983; Pillai and Bikle, 1991). Given
the observation that both vitamin D3 and PG affect keratinocyte
differentiation, we examined the potential link among PG biosynthesis,
keratinocyte differentiation, and vitamin D3 by testing the effects of
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not increase in response to cholecalciferol treatment;
however, unlike COX-1 and cPLA2 expression, COX-
2 mRNA and COX-2 protein expression increased in
response to cholecalciferol treatment. Calphostin C, a
potent protein kinase C inhibitor, significantly reduced
cholecalciferol-induced PGE2 production by inhibiting
cholecalciferol-enhanced COX-2 mRNA and protein
expression. These results indicate that (i) 1a,25(OH)2D3
does not induce PGE2 biosynthesis in keratinocytes, (ii)
cholecalciferol-induced PGE2 production is primarily
COX-2 dependent, and (iii) cholecalciferol enhances both
COX-2 mRNA and protein expression, via a protein
kinase C-dependent mechanism in human keratinocytes.
Furthermore, cholecalciferol increased total cellular
transglutaminase activity dose dependently, suggesting a
potential role for cholecalciferol in regulating the differen-
tiation of human keratinocytes. Key words: cyclooxygenase/
cytosolic phospholipase A2/protein kinase C. J Invest Dermatol
111:634–639, 1998
vitamin D3 on the PGE2 biosynthesis and differentiation of human
keratinocytes.
The metabolism of vitamin D3 has been well elucidated. Initially,
7-dehydroxycholesterol, provitamin D3 is converted to cholecalciferol
by ultraviolet irradiation in skin (Holick, 1981). Cholecalciferol appears
to possess only modest biologic activity; however, when hydroxylated
in the liver and kidney to form 1α,25-dihydroxyvitamin D3
[1α,25(OH)2D3], its biologic activity is greatly enhanced by the time
it is ultimately circulated to target cells (Niendorf et al, 1987; Reichel
et al, 1989; Walters, 1992). In contrast to the well-established mechanism
of action of 1α,25(OH)2D3 on various cell functions, there is little
information in the literature regarding the potential effects of cholecalci-
ferol, the precursor of 1α,25(OH)2D3, on cell function. Because
cholecalciferol is both a major keratinocyte metabolite and a substrate
for the formation of 1α,25(OH)2D3, we compared the effects of
cholecalciferol and 1α,25(OH)2D3 on keratinocyte PGE2 biosynthesis
and differentiation. Studies were performed using both a nontumorig-
enic human keratinocyte cell line, HaCaT, and normal human epidermal
keratinocytes (NHEK). HaCaT cells were derived from a normal skin
specimen and have maintained substantial differentiation potential in
culture (Boukamp et al, 1988).
Here, we show that cholecalciferol significantly enhanced PGE2
production in human keratinocytes by enhancing COX-2 mRNA
and protein expression, and 1α,25(OH)2D3 had no effect on PGE2
production. We found that cholecalciferol-induced COX-2 mRNA
and protein expression and PGE2 production was inhibited by the
protein kinase C (PKC) inhibitor, calphostin C. These findings indicate
that cholecalciferol plays a more important role in regulating PGE2
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Figure 1. Dose–response of vitamin D3-induced PGE2 production.
Confluent HaCaT cells (circles) and NHEK (squares) were treated with the
indicated final concentrations of cholecalciferol (solid symbols) or 1α,25(OH)2D3
(open symbols). After 24 h, the media were collected from identically treated
duplicated wells and analyzed for PGE2 as described in Materials and Methods.
The data presented are representative of five separate experiments.
biosynthesis in keratinocytes than 1α,25(OH)2D3. Furthermore, we
show the possibility that cholecalciferol plays a role in keratinocyte
differentiation using increased transglutaminase activity as a differenti-
ation marker (Thacher and Rice, 1985). These results also suggest that
a re-evaluation of the importance of cholecalciferol in keratinocyte
signal transduction and as a modulator of keratinocyte differentiation
is warranted and may provide new insights into the treatment of
disorders of keratinocyte differentiation, especially psoriasis.
MATERIALS AND METHODS
Materials Anti-PGE2 antibody was purchased from Upstate Biotechnology
(Lake Placid, NY). [3H]PGE2, [
32P]dCTP, and [3H]putrescine were obtained
from DuPont-NEN (Boston, MA). Rabbit polyclonal anti-COX-1 and COX-
2 anti-sera and cDNA probes for COX-1 and COX-2 were purchased
from Oxford Biomedical Research (Oxford, MI). Monoclonal anti-cytosolic
phospholipase A2 (cPLA2) antibody was purchased from Santa Cruz Biotechno-
logy (Santa Cruz, CA) and the cPLA2 cDNA probe was a gift from the Genetics
Institute (Cambridge, MA). Cholecalciferol and Sulindac were obtained from
Sigma (St. Louis, MO). NS398, calphostin C, and 1α,25(OH)2D3 were
purchased from Calbiochem (La Jolla, CA).
Cell culture HaCaT cells were kindly provided by Dr. L. Matrisian (Vanderbilt
University, Nashville, TN) with the permission of Dr. Nobert E. Fusenig
(German Cancer Research Center, Heidelberg, Germany). NHEK were pur-
chased from Clonetics (San Diego, CA). HaCaT cells (passages 35–60) and
NHEK (passages 3–6) were cultured in keratinocyte growth medium (Clonetics)
and incubated under sterile conditions in humidified atmosphere with 5% CO2
at 37°C. Cells were subcultured at 70%–80% confluency. Culture medium was
replaced by keratinocyte growth medium minus hydrocortisone for treatment.
PGE2 measurement PGE2 was measured by the radioimmunoassay based
upon the competition of PGE2 in the test sample with labeled PGE2 for anti-
PGE2 antibody binding site. A 10–100 µl aliquot of culture medium was added
to RIA assay buffer (0.1 mM phosphate buffer, pH 7.4, containing 0.9% sodium
chloride, 0.1% sodium azide, and 0.1% gelatin), mixed with the appropriate
amount of labeled tracer and reconstituted anti-serum. The mixture was
incubated overnight at 4°C. Assay tubes were then placed on ice and 1 ml of
cold charcoal–dextran suspension was added. After a 15 min incubation, the
tubes were centrifuged at 2200 3 g for 10 min at 4°C. The supernatants were
decanted into scintillation vials and radioactivity was determined by scintillation
spectrometry. Per cent binding was compared against a standard curve and the
amount of PGE2 in the sample was calculated.
Western immunoblotting Keratinocytes grown in 10 cm Falcon plastic
dishes were pelleted in phosphate-buffered saline containing 1 µg leupeptin per
ml, 0.03% Aprotinin, 2 mM phenylmethylsulfonyl fluoride, and 2 mM
ethylenediamine tetraacetic acid, pH 7.2. Proteins were obtained by resuspending
the pellet in extraction buffer (62.5 mM Tris, 2% sodium dodecyl sulfate,
0.5 mM dithiothreitol, 1 mM fresh phenylmethylsulfonyl fluoride, pH 6.8) and
denaturing the proteins by placing the sample test tubes at 95°C for 5 min.
Figure 2. Transcriptional and translational effects of cholecalciferol on
PGE2 production. (A) Confluent HaCaT cells were treated with 30 µM
cholecalciferol. Total RNA was isolated after 3 h incubation and 15 µg of each
sample was analyzed by northern blot. The blotted membrane was hybridized
with a 32P-labeled COX-1, COX-2, or cPLA2 probe, stripped, and rehybridized
with a glyceraldehyde phosphate dehydrogenase probe. COX-2, 4.2 kb; cPLA2,
2.8 kb; glyceraldehyde phosphate dehydrogenase, 1.4 kb. (B) Confluent HaCaT
cells were treated with 30 µM cholecalciferol for the indicated times, after
which proteins were extracted and 120 µg of each sample was analyzed by
western immunoblotting using anti-COX-1, anti-COX-2, or anti-cPLA2
antibodies. COX-2, 70 kDa; cPLA2, 100 kDa. (C) Confluent HaCaT cells
were treated with 30 µM cholecalciferol in the absence or presence of
COX-1- or COX-2-specific inhibitors, 5 µM Sulindac, or 100 µM NS398,
respectively. After 24 h, the media were collected from wells and analyzed for
PGE2 as described in Materials and Methods. The data shown represent mean
6 SD of triplicate determinations of one representative experiment of three
separate experiments. *Significant difference at p , 0.05. n.d., not detectable.
Identical amounts of protein were electrophoresed in a 7.5% sodium dodecyl
sulfate/polyacrylamide gel and transferred onto a polyvinylidene difluoride
membrane. The membrane was blocked with 3% bovine serum albumin in
Tris-buffered saline with 0.1% Tween 20 and incubated with either anti-COX-
1, anti-COX-2, or anti-cPLA2 antibodies for 1 h at room temparature. After
incubation with anti-rabbit (COX) or anti-mouse (cPLA2) alkaline phosphatase-
linked immunoglobulin for 1 h at room temperature, the membrane was
exposed to substrate (ECF kit; Amersham, Arlington Heights, IL) for 5 min and
immunoreactive bands were detected using a Storm scanner and FluoroImager
(Molecular Dynamics, Sunnyvale, CA).
Northern blot analysis Total RNA was extracted from keratinocytes grown
in 10 cm dishes using the TRIzol reagent (Tel.Test, Friendwood, TX). Fifteen
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Figure 3. Effect of PKC inhibiton on cholecalciferol-induced PGE2
production. Confluent HaCaT cells were treated with 30 µM cholecalciferol
in the absence or presence of 500 nM calphostin C. After 24 h, the media
were collected from wells and analyzed for PGE2 as described in Materials and
Methods. The data shown represent mean 6 SD of triplicate determination of one
representative experiment of five separate experiments. *Significant difference at
p , 0.05.
micrograms of total RNA was denatured at 50°C for 1 h in 8.6% glyoxal, 72%
dimethylsulfoxide, and 14 mM phosphate buffer, pH 6.5, electrophoresed in a
1.2% agarose gel, blotted onto nylon membranes, and then hybridized with the
32P-labeled cDNA probes for 16 h at 60°C. Hybridized membranes were
autoradiographed using Kodak X-Omat AR films (Eastman Kodak, Rochester,
NY) at –80°C. Each membrane was rehybridized to 32P-labeled glyceraldehyde
phosphate dehydrogenase cDNA to verify that all lanes were loaded with an
equal amount of RNA.
Transglutaminase assay Keratinocytes grown in a 6 cm dish were retrieved
into 1 ml of extraction buffer (2 mM HEPES buffer, pH 7.2, and 2 mM
ethylenediamine tetraacetic acid) and homogenized in a Dounce homogenizer.
The entire homogenate was centrifuged at 600 3 g for 10 min. Enzyme activity
in the supernatant fraction was measured following the Ca21-dependent
incorporation of [3H]putrescine into NN9-dimethylcaseine. The incubation
mixture contained 100 mM Tris/HCl buffer, pH 8.3, 1 mM CaCl2 1 mM
dithiothreitol, 0.1% Triton X, 0.5 mg NN9-dimethylcaseine, 0.5 µCi [3H]putres-
cine, and 100 µl supernatant in a final volume of 250 µl; incubation was for
30 min at 37°C. After acidification with 10% trichloroacetic acid, the precipitated
caseine was spotted on Whatman GF/A filters, rinsed by 5% trichloroacetic
acid, and counted by liquid scintillation counter.
RESULTS AND DISCUSSION
Cholecalciferol, not 1a,25(OH)2D3, induces PGE2 biosynthesis
in human keratinocytes We tested the ability of cholecalciferol
and 1α,25(OH)2D3 to induce PGE2 biosynthesis in human ker-
atinocytes. These studies were performed using concentrations in
keeping with the observation that physiologic plasma concentrations
of cholecalciferol are usually 100-fold higher than 1α,25(OH)2D3
(Behrman et al, 1996). As shown in Fig 1, cholecalciferol induced a
dose-dependent increase in PGE2 biosynthesis in both HaCaT and
NHEK cells, whereas 1α,25(OH)2D3 had no effect on PGE2 production
even at concentrations 100–1000-fold higher than normal physiologic
amounts. At 60 µM cholecalciferol, µ4-fold more PGE2 was synthe-
sized by both HaCaT and NHEK cells when compared with untreated
controls. This is the first report to disclose this effect of cholecalciferol
Figure 4. Effects of PKC inhibitor on cholecalciferol-induced COX-2
mRNA and protein expression. (A) Confluent HaCaT cells were treated
with 30 µM cholecalciferol in the absence or presence of 500 nM calphostin
C. Total RNA was isolated after 3 h incubation and 15 µg of each sample was
northern blotted using 32P-labeled COX-2 and glyceraldehyde phosphate
dehydrogenase probes. (B) Confluent HaCaT cells were treated under the same
conditions as shown in (A), after which sample proteins were extracted and
120 µg of each sample was analyzed by western immunoblotting using anti-
COX-2 antibody.
Figure 5. Time course of cholecalciferol-induced PGE2 production.
Confluent HaCaT cells were treated with 40 µM cholecalciferol. At indicated
times, the media were collected from identically treated triplicate wells and
analyzed for PGE2 as described in Materials and Methods. The data shown are
from three separate experiments and the bars represent mean 6 SD.
and the lack of the effect of 1α,25(OH)2D3. We investigated the
upstream signal transduction of cholecalciferol-induced PGE2 pro-
duction.
COX-2 expression is induced by cholecalciferol in human
HaCaT cells We examined the effects of cholecalciferol on the
expression of COX-1, COX-2, and cPLA2, each of which plays a
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Figure 6. Time course of cholecalciferol-induced COX activity and
inhibition by PKC inhibitor. Confluent HaCaT cells were treated with
40 µM cholecalciferol in the absence or presence of 500 nM calphostin C. At
indicated times, the media were removed, the cells were washed, and fresh
media containing 50 µM arachidonic acid were added. After incubation for
15 min, 15 µl of media were collected from identically treated triplicate wells
and analyzed for PGE2 as a measure of total COX activity. The bars represent
mean 6 SD from three separate determinations taken from a representative
experiment performed three times.
Figure 7. Effects of cholecalciferol and exogenous PGE2 on induction
of transglutaminase activity. Confluent human keratinocytes were treated
with cholecalciferol or PGE2 at indicated concentrations. PGE2 concentration
at 10–1 µM corresponds approximately to 3500 pg per 100 µl. After 48 h, cells
were homogenated and transglutaminase activity was measured as described in
Materials and Methods. Values are expressed as the percentage change in activity,
which is represented by CPM per µg protein, in comparison with control
samples. Assays were performed in triplicate and the data shown are represented
as mean 6 SD in two separate experiments. *Significant difference at p , 0.05.
potentially critical role in regulating PGE2 biosynthesis. When HaCaT
cells were incubated with 30 µM cholecalciferol, COX-2 mRNA and
COX-2 protein expression were both significantly enhanced by 3 h
when compared with the barely detectable levels seen in untreated
cells (Fig 2A, B). Conversely, we were unable to detect either
constitutive or cholecalciferol-induced COX-1 protein. Using low
stringency northern analyses, COX-1 mRNA could be detected;
however, COX-1 mRNA was undetectable when the same conditions
for COX-2 northern analyses were used. Although cPLA2 mRNA
and protein were constitutively expressed in control keratinocytes,
treatment with cholecalciferol did not increase cPLA2 expression
(Fig 2A, B). Together, these results indicate that the ability of
cholecalciferol to induce PGE2 biosynthesis is based predominantly
upon its ability to increase COX-2 (mRNA and protein) expression.
In order to support the hypothesis that cholecalciferol-mediated
PGE2 biosynthesis is COX-2 driven, the effects of NS398, a selective
inhibitor of COX-2, was tested on cholecalciferol-induced PGE2
production. At 100 µM NS398, a concentration previously reported
to have no effect on COX-1 activity (Copeland et al, 1994), cholecalci-
ferol-induced PGE2 production was significantly inhibited (Fig 2C).
On the other hand, Sulindac, a selective inhibitor of COX-1, did not
inhibit PGE2 production, indicating that COX-2, not COX-1, medi-
ates cholecalciferol induced PGE2 biosynthesis.
COX-1 is constitutively expressed in most tissues to perform
‘‘housekeeping’’ functions (DeWitt and Smith, 1988), whereas COX-
2 is induced in response to a variety of agents including mitogens and
cytokines (DeWitt and Smith, 1988; Maier et al, 1990; Xie et al, 1991;
Hla and Neilson, 1992; O’Banion et al, 1992; Reddy and Herschman,
1994). Interestingly, although others have shown the constitutive
expression of COX-1 protein in normal human keratinocytes (Scholz
et al, 1995; Leong et al, 1996), we were unable to detect COX-1
mRNA or protein in immortalized keratinocytes (HaCaT). This
discrepancy may be explained on the basis of the different karyotypes
of normal versus immortalized keratinocytes; although HaCaT cells
differentiate normally, the karyotype of the stem line is hypotetraploid
(mode of 82) after passage 17. Chromosome 1 and 9, where the COX-
2 and COX-1 genes are located, are tetraploid and diploid, respectively
(Boukamp et al, 1988). Because of this altered karyotype, it may be
possible that the constitutive expression of COX-1 was dominated by
that of COX-2.
One primary enzyme in addition to COX, which often exerts
regulatory control over agonist-induced PGE2 production, is cytosolic
phospholipase A2 (cPLA2). The agonist-promoted activation of cPLA2
has been observed in a variety of cells (Wijkander and Sundler, 1992;
Qiu et al, 1993; Rao et al, 1994; Xing and Insel, 1996). Clearly, the
complete activation of cPLA2 requires phosphorylation, most likely
MAP kinase mediated (Lin et al, 1993), along with an increase in
intracellular Ca21 (Serhan et al, 1996). In this study, however, we
failed to detect an increase in the phosphorylation of cPLA2 in response
to cholecalciferol, further supporting our contention that COX-2 is
the rate-limiting factor in cholecalciferol-mediated PGE2 biosynthesis
in HaCaT cells.
PKC inhibition reduces cholecalciferol-induced PGE2
production Because the involvement of the PKC pathway in COX
expression and PGE2 production has been reported in fibroblasts and
glial cells (Vezza et al, 1996; Bauer et al, 1997), the functional
contribution of PKC signaling in cholecalciferol-mediated PGE2 pro-
duction in HaCaT cells was tested utilizing calphostin C (500 nM), a
potent and specific PKC inhibitor (Kobayashi et al, 1989). As shown
in Fig 3, calphostin C significantly abrogated the effects of cholecalci-
ferol on PGE2 production.
PKC inhibition reduces cholecalciferol-induced COX-2 mRNA
and protein expression Next, we examined the effects of calphostin
C on cholecalciferol-induced COX-2 mRNA and protein expression
in HaCaT cells. As shown in Fig 4, calphostin C inhibited both COX-
2 mRNA and protein expression induced by cholecalciferol; however,
COX-2 protein expression was inhibited more significantly than
mRNA, which decreased about 35% as determined by densitometry,
implying both the transcriptional and the translational regulation of
COX-2 expression by PKC.
The kinetics of cholecalciferol-induced PGE2 synthesis As
shown in Fig 5, HaCaT cells were incubated with cholecalciferol for
10 min, 30 min, 1 h, 2 h, 4 h, and 8 h, respectively. Cholecalciferol
significantly induced PGE2 production by 10 min and the total amount
of PGE2 synthesized within a 24 h period reached 80% of maximum
within 1 h.
The effects of exogenous arachidonic acid and calphostin C on
cholecalciferol-induced PGE2 production . In an effort to address
the issue of the importance of substrate availability, PKC activity, and
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COX-2 expression in regulating PGE2 biosynthesis, particularly at
early time points when PGE2 was produced prior to COX-2 protein
induction, we performed the following experiment. After HaCaT cells
were treated with cholecalciferol, plus and minus calphostin C, for
increasing periods of time, culture media were replaced by fresh media
containing 50 µM AA. PGE2 levels were measured after a 15 min
incubation. Addition of excess exogenous AA precludes the potential
rate-limiting effect of substrate availability and is a measurement of
total COX (COX-1 and COX-2 combined) activity. Figure 6 shows
that in the presence of added AA, there is an early production of PGE2
very similar to that observed in cells utilizing only endogenous AA as
substrate (Fig 5). The fact that the addition of substrate (AA) has little
effect on the time course of PGE2 biosynthesis clearly indicates
that COX expression, not substrate availability, is rate-limiting for
cholecalciferol-mediated PGE2 biosynthesis in HaCaT cells. Further,
cholecalciferol-induced PGE2 biosynthesis in the presence of excess
AA was significantly inhibited by calphostin C. These findings indicate
that cholecalciferol rapidly induces COX activity at early time points,
that COX activity and PGE2 production are induced in a parallel time
frame, and that both COX-2 expression and PGE2 biosynthesis are
inhibited by calphostin C. These results strongly suggest that PKC
plays a role in cholecalciferol signal transduction with respect to both
the early induction of COX activity and the subsequent increase in
COX-2 mRNA and protein expression in keratinocytes.
Cholecalciferol induces total transglutaminase activity Previous
studies showing the association between elevated endogenous PGE2
levels and the differentiation of keratinocytes (Evans et al, 1993) led us
to examine the effect of cholecalciferol on keratinocyte differentiation.
Transglutaminase activity was assayed as a biologic marker of ker-
atinocyte differentiation (Thacher and Rice, 1985). As shown in
Fig 7, total transglutaminase activity was induced by incubation of
keratinocytes with cholecalciferol or by the addition of exogenous
PGE2 for 48 h. This result suggests a possible role for cholecalciferol
as an inducer of keratinocyte differentiation via its ability to induce
PGE2 biosynthesis. Transglutaminase activity was also induced by
1α,25(OH)2D3 in accordance with the previous literature (Hosomi
et al, 1983; Pillai and Bikle, 1991) (data not shown). The possibility
that both cholecalciferol and 1α,25(OH)2D3 are capable of inducing
keratinocyte differentiation, whereas only cholecalciferol induces PGE2
production, suggests that there may be PGE2-dependent and PGE2-
independent pathways mediating keratinocyte differentiation. At this
time, based upon our data showing that cholecalciferol and PGE2
increased total transglutaminase activity, we can only speculate that
keratinocyte differentiation is induced by cholecalciferol, via increased
PGE2 biosynthesis, because increases in cytosolic transglutaminase,
COX-2 expression, and PGE2 synthesis have also been linked to
apoptosis in keratinocytes and other tissues (Tsujii and DuBois, 1995;
Szondy et al, 1997; Sheng et al, 1998). Therefore, the effects of
cholecalciferol and PGE2 on differentiation must be validated by
discriminating between the cytosolic and the membrane-bound trans-
glutaminase isotypes, the latter isotype being specifically involved in
the induction of keratinocyte differentiation (Rice et al, 1992).
In conclusion, we provide evidence that cholecalciferol induces
COX-2 mRNA and protein expression under regulation of PKC,
resulting in enhanced PGE2 production, and that cholecalciferol may
affect keratinocyte differentiation. These findings may provide new
insights into the treatment of disorders of keratinocyte differentiation
such as psoriasis, because our data suggest that cholecalciferol may be
a more keratinocyte-specific agent than the activated forms of viatmin
D3. In order to avoid the cytotoxicity of vitamin D3 in the treatment
of psoriasis, analogs of vitamin D3 such as 1α,25(OH)2D3 (calcitriol),
a side-chain modification of 1α,25(OH)2D3 (calcipotriol), or
1,24(OH)2D3 (tacalcitol) are currently used; each of these compounds
appear to induce keratinocyte differentiation through the same receptor
(Sato et al, 1996). Interestingly, our data suggest that cholecalciferol
may signal via a different pathway than 1α,25(OH)2D3 in keratinocytes
because cholecalciferol induces PGE2 biosynthesis whereas
1α,25(OH)2D3 does not. Future studies will focus on (i) the specificity
of vitamin D3 metabolites as modulators of keratinocyte function, (ii)
defining the relationships among cholecalciferol, COX, PGE2, and
keratinocyte differentiation, and (iii) determining the respective roles
of the cyclooxygenases as regulators of cellular proliferation and
differentiation.
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